[Skip to Navigation]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Navigation Landing]

December 2020 - April 2015

Decade

Year

Issue

January 2021, Vol 7, No. 1, Pages 20-140

Original Investigation

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2021;7(1):34-41. doi:10.1001/jamaoncol.2020.5660

This phase 3 randomized clinical trial assesses the efficacy of a clinician-driven treatment choice vs a circulating tumor cell count–driven choice for first-line treatment among women with hormone receptor–positive, ERBB2-negative metastatic breast cancer.

Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial

Abstract Full Text
has audio
JAMA Oncol. 2021;7(1):42-50. doi:10.1001/jamaoncol.2020.5774

This nonrandomized clinical trial evaluates molecular recurrence and patient-reported outcomes after tyrosine kinase inhibitor discontinuation in US patients with chronic myeloid leukemia.

Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer

Abstract Full Text
JAMA Oncol. 2021;7(1):52-58. doi:10.1001/jamaoncol.2020.6086

This dynamic cohort study evaluates the regional adoption of genomic testing for prostate cancer and the common trajectories of uptake shared by regions.

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2021;7(1):61-69. doi:10.1001/jamaoncol.2020.5572

This randomized clinical trial evaluates clinical outcomes in patients with ERBB2-negative metastatic breast cancer treated with indoximod plus a taxane.

Effectiveness of Molecular Testing Techniques for Diagnosis of Indeterminate Thyroid Nodules: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2021;7(1):70-77. doi:10.1001/jamaoncol.2020.5935

This randomized clinical trial compares the diagnostic performance between an RNA test and a DNA-RNA test in patients with thyroid nodules.

Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2021;7(1):78-85. doi:10.1001/jamaoncol.2020.5945

This single-arm, phase 2 nonrandomized clinical trial assesses the efficacy and safety of combined pembrolizumab, bevacizumab, and oral metronomic cyclophosphamide in women with recurrent platinum-sensitive, platinum-resistant, or refractory epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Reproductive Outcomes After Breast Cancer in Women With vs Without Fertility Preservation

Abstract Full Text
open access
JAMA Oncol. 2021;7(1):86-91. doi:10.1001/jamaoncol.2020.5957

This cohort study investigates the long-term reproductive outcomes in women who did or did not undergo fertility preservation at the time of breast cancer diagnosis.

Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis

Abstract Full Text
has active quiz
JAMA Oncol. 2021;7(1):92-106. doi:10.1001/jamaoncol.2020.6146

This meta-analysis reviews 21 trials of stereotactic ablative radiotherapy administered to patients with oligometastatic cancer.

Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial

Abstract Full Text
online only
JAMA Oncol. 2021;7(1):e205865. doi:10.1001/jamaoncol.2020.5865

This nonrandomized controlled trial reports the oncological outcomes of the deintensification (from 50 Gy to 36 Gy) of a preoperative radiotherapy regimen for adults with myxoid liposarcoma.

Brief Report

Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

Abstract Full Text
open access
JAMA Oncol. 2021;7(1):107-110. doi:10.1001/jamaoncol.2020.5161

This case series study examines the prevalence of clonal hematopoiesis and its potential interference in prostate cancer cell-free DNA testing.

Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer

Abstract Full Text
online only
JAMA Oncol. 2021;7(1):e205671. doi:10.1001/jamaoncol.2020.5671

This case series examines clinical characteristics, experiences, and outcomes of transgender patients with cancer.

Research Letter

Association Between Surgical Technical Skill and Long-term Survival for Colon Cancer

Abstract Full Text
JAMA Oncol. 2021;7(1):127-129. doi:10.1001/jamaoncol.2020.5462

This cohort study examines the association between surgical technical skill and overall survival following colectomy for colon cancer.

Serial Screening for COVID-19 in Asymptomatic Patients Receiving Anticancer Therapy in the United Arab Emirates

Abstract Full Text
open access has active quiz
JAMA Oncol. 2021;7(1):129-131. doi:10.1001/jamaoncol.2020.5745

This cohort study examines the implementation of a microbiologic screening pilot program in Al Zahra Hospital in the United Arab Emirates for identifying presymptomatic COVID-19 in patients with cancer.

Association of the COVID-19 Outbreak With Patient Willingness to Enroll in Cancer Clinical Trials

Abstract Full Text
open access has active quiz
JAMA Oncol. 2021;7(1):131-132. doi:10.1001/jamaoncol.2020.5748

This survey study examines the attitudes of a large group of cancer survivors toward trial participation during the coronavirus disease 2019 outbreak.

Assessment of Discordance Among Smoldering Multiple Myeloma Risk Models

Abstract Full Text
JAMA Oncol. 2021;7(1):132-134. doi:10.1001/jamaoncol.2020.5585

This cohort study assesses the concordance of 3 models to stratify risk for progression to multiple myeloma in an independent cohort of patients with smoldering multiple myeloma.

Review

The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review

Abstract Full Text
JAMA Oncol. 2021;7(1):113-123. doi:10.1001/jamaoncol.2020.3381

This narrative review discusses developments in pharmacotherapy for patients with advanced hepatocellular carcinoma.

JAMA Oncology Clinical Challenge

Progressive Dry Cough in a Patient With ROS1-Rearranged Lung Adenocarcinoma Undergoing Crizotinib Therapy

Abstract Full Text
has active quiz
JAMA Oncol. 2021;7(1):124-125. doi:10.1001/jamaoncol.2020.2809

A 69-year-old man with a smoking history and complaints of back pain and cough for 2 weeks was found to have a right upper lobe lung mass with multiple lymphadenopathies. What is your diagnosis?

Viewpoint

Metastatic Disease as a Distinct Discipline in Radiation Oncology

Abstract Full Text
JAMA Oncol. 2021;7(1):21-22. doi:10.1001/jamaoncol.2020.1824

This Viewpoint discusses the advantages of having a dedicated metastatic disease radiation oncology program addressing the specific needs of patients with metastatic cancer.

The Day After COVID-19—Time to Rethink Oncology Clinical Research

Abstract Full Text
free access
JAMA Oncol. 2021;7(1):23-24. doi:10.1001/jamaoncol.2020.4240

This Viewpoint discusses how the COVID-19 pandemic may reshape clinical practice and clinical research as new technologies are incorporated and old practices are revisited and revamped.

Oncology’s “Hockey Stick” Moment for the Cost of Cancer Drugs—The Climate Is About to Change

Abstract Full Text
JAMA Oncol. 2021;7(1):25-26. doi:10.1001/jamaoncol.2020.1828

This Viewpoint discusses the potential consequences associated with the rising cost of anticancer drugs and proposes 3 likely responses.

US Food and Drug Administration Support for Oncology Drug Development During COVID-19

Abstract Full Text
free access has active quiz
JAMA Oncol. 2021;7(1):27-28. doi:10.1001/jamaoncol.2020.4975

This Viewpoint seeks to contextualize recent US Food and Drug Administration guidance on clinical trials during COVID-19 to oncology and to share insight regarding regulatory challenges and lessons learned.

Editorial

Evaluating the Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer—Is Not Worse Good Enough?

Abstract Full Text
JAMA Oncol. 2021;7(1):30-31. doi:10.1001/jamaoncol.2020.5460
Invited Commentary

Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia: Updates From the LAST Study on Patient-Reported Outcomes and Biomarkers for Relapse

Abstract Full Text
JAMA Oncol. 2021;7(1):50-51. doi:10.1001/jamaoncol.2020.5772

Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer: Is Rising Utilization Justified by Evidence?

Abstract Full Text
JAMA Oncol. 2021;7(1):59-60. doi:10.1001/jamaoncol.2020.6045

A CHIP in the Armor of Cell-Free DNA–Based Predictive Biomarkers for Prostate Cancer

Abstract Full Text
JAMA Oncol. 2021;7(1):111-112. doi:10.1001/jamaoncol.2020.5140
Cancer Care Chronicles

Hope Shattered, Hope Restored

Abstract Full Text
JAMA Oncol. 2021;7(1):29. doi:10.1001/jamaoncol.2020.5191

This essay describes how an act of kindness can restore one’s hope.

Comment & Response

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases

Abstract Full Text
JAMA Oncol. 2021;7(1):134-135. doi:10.1001/jamaoncol.2020.5466

Deferring a Change in the Standard of Care for Small Cell Lung Cancer Brain Metastases—Reply

Abstract Full Text
JAMA Oncol. 2021;7(1):135-136. doi:10.1001/jamaoncol.2020.5473

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy

Abstract Full Text
JAMA Oncol. 2021;7(1):136-137. doi:10.1001/jamaoncol.2020.5582

Clarification of Definitions of Hyperprogressive Disease During Immunotherapy—Reply

Abstract Full Text
JAMA Oncol. 2021;7(1):137. doi:10.1001/jamaoncol.2020.5591

New Approaches to Cancer Care in a COVID-19 World—The Role of Health and Social Protection Policies

Abstract Full Text
free access
JAMA Oncol. 2021;7(1):137-138. doi:10.1001/jamaoncol.2020.5853

Possible Reverse Causation and Confounding in Study of the Association of Sedentary Behavior With Cancer Mortality

Abstract Full Text
JAMA Oncol. 2021;7(1):138-139. doi:10.1001/jamaoncol.2020.5874

Possible Reverse Causation and Confounding in Study of the Association of Sedentary Behavior With Cancer Mortality—Reply

Abstract Full Text
JAMA Oncol. 2021;7(1):139-140. doi:10.1001/jamaoncol.2020.5877
Correction

Error in Author Byline Order

Abstract Full Text
free access
JAMA Oncol. 2021;7(1):140. doi:10.1001/jamaoncol.2020.6492

Error in Author Affiliation

Abstract Full Text
free access
JAMA Oncol. 2021;7(1):140. doi:10.1001/jamaoncol.2020.6961

Error in Author Name

Abstract Full Text
free access
JAMA Oncol. 2021;7(1):140. doi:10.1001/jamaoncol.2020.7303
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2021;7(1):20. doi:10.1001/jamaoncol.2020.5033
×